TYRO3
TYRO3 Molecule Information
Name:TYRO3 protein tyrosine kinase
Target Synonym:BYK ;Tyrosine-protein kinase RSE;Tyrosine-protein kinase BYK;SKY;Tyrosine-protein kinase receptor TYRO3;TIF;Tyrosine-protein kinase TIF;TYRO3;Tyrosine-protein kinase DTK;RSE;Tyrosine-protein kinase SKY;DTK
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Approved
TYRO3 Molecule Synonym Name
TYRO3,BYK,DTK,RSE,SKY,TIF
TYRO3 Molecule Background
Tyrosine-protein kinase receptor TYRO3 is also known as Tyrosine-protein kinase BYK, DTK, RSE, SKY, TIF, which belongs to the protein kinase superfamily, Tyr protein kinase family and AXL/UFO subfamily. TYRO3 regulates many physiological processes including cell survival, migration and differentiation. TYRO3 activates the AKT survival pathway, including nuclear translocation of NF-kappa-B and up-regulation of transcription of NF-kappa-B-regulated genes. TYRO3 interacts (via N-terminus) with extracellular ligands TULP1 and GAS6 By similarity and also interacts with PIK3R1, this interaction increases PI3-kinase activity.
TYRO3 References
TYRO3 Public Drug Information
Name |
Research Code |
Research Phase |
Company |
First Brand Name |
First Approved Country |
First Indication |
First Approved Company |
First Approved Date |
Indications |
Clinical Trials |
Cabozantinib S-malate |
XL-184; BMS-907351,BMS907351,XL184,XL 184,BMS 907351 |
Approved |
Exelixis, Ipsen, Takeda |
COMETRIQ |
fda |
Medullary thyroid cancer (MTC) |
EXELIXIS |
2012-11-29 |
Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Medullary thyroid cancer (MTC), Hepatocellular carcinoma (HCC) |
Details
|
TYRO3 Clinical Drug Information
Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
LDC-1267 |
LDC-1267 |
Preclinical |
Max Planck Innovation, Lead Discovery Center |
Cancer |
Details
|
Insulin transdermal patch (Zosano Pharma) |
|
Phase Ⅰ |
Zosano |
Diabetes |
Details
|
Insulin tregopil (Biocon) |
IN-105; NIN-058; GW-843362; HIM-2,IN 105; NIN 058; GW 843362; HIM 2,IN105; NIN058; GW843362; HIM2 |
Phase Ⅲ |
Biocon, Bristol-Myers Squibb |
Type 1 diabetes, Type 2 diabetes |
Details
|
Insulin transdermal (Phosphagenics) |
TPM-02,TPM 02,TPM02 |
Phase Ⅱ |
Phosphagenics |
Type 1 diabetes, Type 2 diabetes |
Details
|
RXDX-106 |
RXDX-106 |
Phase Ⅰ |
Teva, Daiichi Sankyo, Roche |
Solid tumours |
Details
|
Insulin biosimilar (SemBioSys/Tasly) |
SBS-1000 |
Phase Ⅲ |
Tasly Pharmaceuticals, SemBioSys |
Type 1 diabetes |
Details
|